SG11201901273TA - Blood plasma fractions as a treatment for aging-associated cognitive disorders - Google Patents
Blood plasma fractions as a treatment for aging-associated cognitive disordersInfo
- Publication number
- SG11201901273TA SG11201901273TA SG11201901273TA SG11201901273TA SG11201901273TA SG 11201901273T A SG11201901273T A SG 11201901273TA SG 11201901273T A SG11201901273T A SG 11201901273TA SG 11201901273T A SG11201901273T A SG 11201901273TA SG 11201901273T A SG11201901273T A SG 11201901273TA
- Authority
- SG
- Singapore
- Prior art keywords
- california
- international
- aging
- blood plasma
- pct
- Prior art date
Links
- 210000002381 plasma Anatomy 0.000 title abstract 3
- 208000010877 cognitive disease Diseases 0.000 title abstract 2
- 230000002431 foraging effect Effects 0.000 title 1
- 240000005020 Acaciella glauca Species 0.000 abstract 3
- 235000003499 redwood Nutrition 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000003405 preventing effect Effects 0.000 abstract 2
- 229940125652 NAMI Drugs 0.000 abstract 1
- 208000027626 Neurocognitive disease Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- PEVNIEPIRVCPAW-UHFFFAOYSA-J sodium;1h-imidazole;methylsulfinylmethane;ruthenium(3+);tetrachloride Chemical compound [Na+].[Cl-].[Cl-].[Cl-].[Cl-].[Ru+3].CS(C)=O.C1=CNC=N1 PEVNIEPIRVCPAW-UHFFFAOYSA-J 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A61K38/385—Serum albumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662376529P | 2016-08-18 | 2016-08-18 | |
US201662412258P | 2016-10-24 | 2016-10-24 | |
PCT/US2017/029953 WO2018034712A1 (en) | 2016-08-18 | 2017-04-27 | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901273TA true SG11201901273TA (en) | 2019-03-28 |
Family
ID=61196950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901273TA SG11201901273TA (en) | 2016-08-18 | 2017-04-27 | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
Country Status (28)
Country | Link |
---|---|
US (2) | US20190321449A1 (hr) |
EP (2) | EP3995140A1 (hr) |
JP (3) | JP7316931B2 (hr) |
KR (3) | KR20240036720A (hr) |
CN (2) | CN109963582B (hr) |
AU (2) | AU2017312722B2 (hr) |
BR (1) | BR112019003172A2 (hr) |
CA (1) | CA3033051A1 (hr) |
CL (1) | CL2019000304A1 (hr) |
CY (1) | CY1124695T1 (hr) |
DK (1) | DK3484502T3 (hr) |
ES (1) | ES2899147T3 (hr) |
HR (1) | HRP20211628T1 (hr) |
HU (1) | HUE056294T2 (hr) |
IL (2) | IL264660B2 (hr) |
LT (1) | LT3484502T (hr) |
MA (1) | MA45692B1 (hr) |
MD (1) | MD3484502T2 (hr) |
MX (1) | MX2019001718A (hr) |
NZ (1) | NZ750885A (hr) |
PL (1) | PL3484502T3 (hr) |
PT (1) | PT3484502T (hr) |
RS (1) | RS62558B1 (hr) |
SG (1) | SG11201901273TA (hr) |
SI (1) | SI3484502T1 (hr) |
UA (1) | UA126232C2 (hr) |
WO (1) | WO2018034712A1 (hr) |
ZA (1) | ZA202004834B (hr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112019022402A2 (pt) * | 2017-04-26 | 2020-05-19 | Alkahest Inc | regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo |
SG11202010115RA (en) | 2018-05-15 | 2020-11-27 | Alkahest Inc | Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase |
CN110724176B (zh) * | 2018-07-16 | 2021-10-26 | 北京豪思生物科技有限公司 | 一种治疗阿尔茨海默症的血浆蛋白分离物及其制备方法和应用 |
CN110787187B (zh) * | 2018-07-16 | 2022-05-13 | 北京豪思生物科技股份有限公司 | 一种增强记忆力和提高认知功能的血浆混合物及其制备方法和应用 |
MX2021000707A (es) * | 2018-07-20 | 2021-03-25 | Alkahest Inc | Regimen de dosificacion para el tratamiento de deterioros cognitivos y motores con plasma de sangre y productos de plasma de sangre. |
CA3115308A1 (en) * | 2018-10-26 | 2020-04-30 | Alkahest, Inc. | Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery |
CN110448686B (zh) * | 2019-09-19 | 2022-11-04 | 北京豪思生物科技股份有限公司 | 铜蓝蛋白联合运铁蛋白的应用 |
WO2021062007A1 (en) * | 2019-09-25 | 2021-04-01 | Cytegen Corp. | Treatment of mitochondrial deficits and age-related diseases using blood products |
AU2020378245A1 (en) | 2019-11-04 | 2022-04-07 | Alkahest, Inc. | Blood plasma fractions for use in muscle regeneration |
US11484551B2 (en) | 2019-11-20 | 2022-11-01 | Alkahest, Inc. | Method of treating liver failure with plasma fraction IV-4 |
JP2023502496A (ja) | 2019-11-20 | 2023-01-24 | アルカヘスト,インコーポレイテッド | 肝臓再生に使用するための血漿画分 |
AU2022376563A1 (en) | 2021-11-01 | 2023-12-07 | Alkahest, Inc. | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
WO2024102244A1 (en) * | 2022-11-11 | 2024-05-16 | Alkahest, Inc. | Blood plasma fractions for improvement of myelination |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3869431A (en) | 1973-03-12 | 1975-03-04 | Firestone Tire & Rubber Co | Polyamides and their production |
US4624780A (en) | 1982-06-28 | 1986-11-25 | Alpha Therapeutic Corporation | Fractionation of blood plasma |
DE3612137A1 (de) * | 1986-04-10 | 1987-10-15 | Biotest Pharma Gmbh | Steriles plasmaaustauschmittel |
US5138034A (en) * | 1989-07-12 | 1992-08-11 | The Green Cross Corporation | Method of fractionating plasma proteins |
US5110907A (en) | 1989-08-01 | 1992-05-05 | Alpha Therapeutic Corporation | Factor viii complex purification using heparin affinity chromatography |
US5288853A (en) | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
US5219995A (en) | 1992-07-14 | 1993-06-15 | Alpha Therapeutic Corporation | Plasma fraction purification |
US5561115A (en) * | 1994-08-10 | 1996-10-01 | Bayer Corporation | Low temperature albumin fractionation using sodium caprylate as a partitioning agent |
JP4402885B2 (ja) * | 2001-05-11 | 2010-01-20 | 財団法人化学及血清療法研究所 | 新規な神経変性疾患治療剤 |
AU2003303198A1 (en) * | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
US20040146565A1 (en) * | 2003-01-28 | 2004-07-29 | Lauridsen Group Incorporated | First lipoprotein fraction and therapeutic compositions of same |
US20130121979A1 (en) * | 2003-12-29 | 2013-05-16 | Allan Mishra | Method of treating cancer using platelet compositions |
ES2257225B1 (es) | 2006-02-17 | 2007-03-16 | Grifols, S.A | Preparacion terapeutica de fviia de muy alta pureza y metodo para su obtencion. |
ES2332846B1 (es) * | 2007-10-26 | 2010-07-08 | Grifols, S.A. | Utilizacion de albumina humana terapeutica para la preparacion de un medicamento para el tratamiento de pacientes afectados por desordenes cognitivos. |
EP2271382B1 (en) | 2008-04-15 | 2013-03-13 | Grifols Therapeutics Inc. | Two-stage ultrafiltration/diafiltration |
US20090297485A1 (en) * | 2008-05-28 | 2009-12-03 | Allan Mishra | Compositions and methods for treating psychiatric and neurodegenerative disorders |
AU2013203043B2 (en) * | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
JP6424210B2 (ja) * | 2013-05-06 | 2018-11-14 | バクスアルタ インコーポレイテッド | プールされた免疫グロブリンgを用いたアルツハイマー病の亜集団の治療 |
CN106163530A (zh) * | 2013-12-09 | 2016-11-23 | 小利兰·斯坦福大学托管委员会 | 用于治疗衰老相关病症的方法和组合物 |
ES2524516B1 (es) | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
US10525107B2 (en) * | 2016-08-18 | 2020-01-07 | Alkahest, Inc. | Blood plasma fractions as a treatment for aging-associated cognitive disorders |
BR112019022402A2 (pt) * | 2017-04-26 | 2020-05-19 | Alkahest Inc | regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo |
US11040068B2 (en) * | 2017-04-26 | 2021-06-22 | Alkahest, Inc. | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products |
-
2017
- 2017-04-27 CA CA3033051A patent/CA3033051A1/en active Pending
- 2017-04-27 DK DK17841780.4T patent/DK3484502T3/da active
- 2017-04-27 HU HUE17841780A patent/HUE056294T2/hu unknown
- 2017-04-27 KR KR1020247007926A patent/KR20240036720A/ko active Search and Examination
- 2017-04-27 EP EP21192528.4A patent/EP3995140A1/en active Pending
- 2017-04-27 PL PL17841780T patent/PL3484502T3/pl unknown
- 2017-04-27 WO PCT/US2017/029953 patent/WO2018034712A1/en unknown
- 2017-04-27 CN CN201780057412.0A patent/CN109963582B/zh active Active
- 2017-04-27 ES ES17841780T patent/ES2899147T3/es active Active
- 2017-04-27 IL IL264660A patent/IL264660B2/en unknown
- 2017-04-27 LT LTEPPCT/US2017/029953T patent/LT3484502T/lt unknown
- 2017-04-27 SI SI201730964T patent/SI3484502T1/sl unknown
- 2017-04-27 IL IL304946A patent/IL304946A/en unknown
- 2017-04-27 RS RS20211337A patent/RS62558B1/sr unknown
- 2017-04-27 AU AU2017312722A patent/AU2017312722B2/en active Active
- 2017-04-27 MX MX2019001718A patent/MX2019001718A/es unknown
- 2017-04-27 EP EP17841780.4A patent/EP3484502B1/en active Active
- 2017-04-27 SG SG11201901273TA patent/SG11201901273TA/en unknown
- 2017-04-27 UA UAA201901438A patent/UA126232C2/uk unknown
- 2017-04-27 HR HRP20211628TT patent/HRP20211628T1/hr unknown
- 2017-04-27 KR KR1020227025297A patent/KR20220107322A/ko not_active IP Right Cessation
- 2017-04-27 CN CN202211658689.8A patent/CN115957309A/zh active Pending
- 2017-04-27 MA MA45692A patent/MA45692B1/fr unknown
- 2017-04-27 KR KR1020197007543A patent/KR20190032614A/ko not_active IP Right Cessation
- 2017-04-27 MD MDE20190622T patent/MD3484502T2/ro unknown
- 2017-04-27 JP JP2019508828A patent/JP7316931B2/ja active Active
- 2017-04-27 PT PT178417804T patent/PT3484502T/pt unknown
- 2017-04-27 BR BR112019003172A patent/BR112019003172A2/pt not_active Application Discontinuation
- 2017-04-27 NZ NZ750885A patent/NZ750885A/en unknown
-
2019
- 2019-02-05 CL CL2019000304A patent/CL2019000304A1/es unknown
- 2019-06-28 US US16/456,717 patent/US20190321449A1/en not_active Abandoned
-
2020
- 2020-01-09 AU AU2020200181A patent/AU2020200181B2/en active Active
- 2020-07-16 ZA ZA2020/04834A patent/ZA202004834B/en unknown
-
2021
- 2021-11-05 CY CY20211100958T patent/CY1124695T1/el unknown
- 2021-12-15 JP JP2021203571A patent/JP7447069B2/ja active Active
-
2022
- 2022-01-24 US US17/582,974 patent/US20220152161A1/en active Pending
-
2023
- 2023-08-17 JP JP2023133021A patent/JP2023156459A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901273TA (en) | Blood plasma fractions as a treatment for aging-associated cognitive disorders | |
SG11201909927RA (en) | Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products | |
SG11201906885TA (en) | Methods for the administration of certain vmat2 inhibitors | |
SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201810883TA (en) | Combination therapy | |
SG11201804839WA (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
SG11201805577XA (en) | Techniques for manipulation of two-qubit quantum states and related systems and methods | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201810391RA (en) | Medical devices, systems and methods utilizing permanent magnet and magnetizable feature | |
SG11201808125RA (en) | Methods for solid tumor treatment | |
SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201810443SA (en) | Invasive medical devices including magnetic region and systems and methods | |
SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
SG11201901271VA (en) | Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer | |
SG11201908051RA (en) | Modified human igm constant regions for modulation of complement-dependent cytolysis effector function | |
SG11201807421TA (en) | The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors | |
SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
SG11201808306PA (en) | Treatment of cancer with tg02 | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201810765PA (en) | Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same | |
SG11201807593TA (en) | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer |